Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Inclusion Criteria

• •Histologically confirmed B-cell non-Hodgkin lymphoma (NHL), including any of the following:
• •* Marginal zone lymphoma
• •* Waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma)
• •* Follicular lymphoma
• •* Mantle cell lymphoma
• •Relapsed or refractory disease after ≥ 1 prior therapy
• •Patients with rituximab-refractory disease (defined as having less than a partial response to the prior rituximab-containing regimen) or rituximab-sensitive disease (defined as having a complete response or partial response to the last rituximab-containing regimen \[provided it has been ≥ 3 months since the last dose of rituximab\]) are eligible.
• •Age \>18 years.
• •Eastern Cooperative Oncology Group (ECOG)performance status 0-2.
• •Patients must have normal organ and marrow function as defined below:
• •* Absolute neutrophil count ≥ 1000/μL
• •* Platelets ≥ 75,000/μL
• •* Total bilirubin ≤ 2.0 X institutional upper limit of normal
• •* AST(SGOT)/ALT(SGPT) ≤ 2.5 X institutional upper limit of normal
• •* Creatinine ≤ 2.0 mg/dL
• •Patients who have relapsed after stem cell transplant are eligible for this trial.